LACK OF AN IMPORTANT INFLUENCE OF CYP2D6 OXIDATION STATUS ON THE PHARMACOKINETICS OF MOCLOBEMIDE

被引：0
|
作者：
GUENTERT, TW [1 ]
GRANGE, S [1 ]
BOCK, J [1 ]
WALDBURGER, R [1 ]
BIRNBOECK, H [1 ]
HOFFMANNLAROCHE, F [1 ]
机构：
[1] F HOFFMANN LA ROCHE & CO LTD,CH-4002 BASEL,SWITZERLAND
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1995年 / 57卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：151 / 151
页数：1
相关论文
共 50 条
  • [21] Lack of effect of aprepitant on the pharmacokinetics of hydrodolasetron in CYP2D6 extensive and poor metabolizers.
    Li, X
    Pequignot, E
    Panebianco, D
    Majumdar, A
    Selverian, D
    Rosen, L
    Petty, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P47 - P47
  • [22] Pharmacokinetics of atomoxetine after administration of paroxetine in relation to CYP2D6 genotype status
    Kim, Dong-Hyun
    Lim, Hye-Jin
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    PHARMACOTHERAPY, 2015, 35 (11): : E316 - E317
  • [23] Effects of CYP2D6*10 and CYP2D6*5 alleles on the pharmacokinetics of carvedilol in healthy Koreans.
    Kang, Byung-Sung
    Lee, Hye-In
    Choi, Chang-Ik
    PHARMACOTHERAPY, 2012, 32 (10): : E301 - E301
  • [24] The influence of clomipramine on CYP2D6 activity
    Szewczuk-Boguslawska, Monika
    Kiejna, Andrzej
    Grzesiak, Magdalena
    Beszlej, Jan Aleksander
    Chlebowska, Iwona
    Orzechowska-Juzwenko, Krystyna
    Milejski, Piotr
    PSYCHIATRIA POLSKA, 2007, 41 (02) : 243 - 249
  • [25] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [26] Influence of CYP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects
    Zhang, Xiaodan
    Liu, Chengquan
    Zhou, Shuang
    Xie, Ran
    He, Xu
    Wang, Zhiqi
    Yi, Honghong
    Shu, You
    Wang, Zining
    Hu, Kun
    Ma, Lingyue
    Cui, Yimin
    Zhao, Xia
    Xiang, Jin
    PHARMACOGENOMICS, 2021, 22 (04) : 213 - 223
  • [27] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation:: a study of mutations CYP2D6*3 and CYP2D6*4
    Monek, O
    Paintaud, G
    Bechtel, Y
    Miguet, JP
    Mantion, G
    Bechtel, PR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) : 47 - 52
  • [28] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4
    O. Monek
    G. Paintaud
    Y. Bechtel
    J. P. Miguet
    G. Mantion
    P. R. Bechtel
    European Journal of Clinical Pharmacology, 1998, 54 : 47 - 52
  • [29] Venlafaxine oxidation in vitro is catalysed by CYP2D6
    Otton, SV
    Ball, SE
    Cheung, SW
    Inaba, T
    Rudolph, RL
    Sellers, EM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (02) : 149 - 156
  • [30] Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide
    Bae, Jung-Woo
    Oh, Kyung-Yul
    Yoon, So-Jung
    Shin, Hyo-Bin
    Jung, Eui Hyun
    Cho, Chang-Keun
    Lim, Chang Woo
    Kang, Pureum
    Choi, Chang-Ik
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2020, 43 (11) : 1207 - 1213
12345